BACKGROUND KRAS mutations occur in 35-45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the PIK3CA/PTEN pathway have independently been f...

Treatment of renal cell carcinoma has dramatically changed in the past 5 years, with the approval of six new drugs since 2006. Although treatment algorithms have been reported and updated every year since 2006, the choice of targeted therapy is not always easy. Selecting a targeted agent in metastatic renal cell carcinoma should take into account various parameters, including the status of the ...

PURPOSE The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer. EXPERIMENTAL DESIGN Outcomes of patients who were referred for treatment on phase I clinical trials at The University of Texas MD Anderson Cancer Center (Hou...

In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical development and the ways in which advances in treating HER2-positive breast cancer can be used to inform treatment decisions in other areas of medicine.

Today, personalized cancer therapy with targeted agents has taken center stage, and offers individualized treatment to many. As the mysteries of the genes in a cell's DNA and their specific proteins are defined, advances in the understanding of cancer gene mutations and how cancer evades the immune system have been made. This article provides a basic and simplified understanding of the availabl...

Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded wi...

Cancer is one of the deadliest diseases against humans. To tackle this menace, humans have developed several high-technology therapies, such as chemotherapy, tomotherapy, targeted therapy, and antibody therapy. However, all these therapies have their own adverse side effects. Therefore, recent years have seen increased attention being given to the natural food for complementary therapy, which h...

Activator protein-1 (AP-1) is a transcription factor that consists of diverse group members including Jun, Fos, Maf, and ATF. AP-1 involves number processes such as proliferation, migration, invasion in cells. Dysfunctional activity associated with cancer initiation, development, invasion, migration drug resistance. Therefore, potential target for targeted therapy. Currently, some small molecul...

Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded wi...